154 related articles for article (PubMed ID: 21228103)
21. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice.
Sung SH; Ziyadeh FN; Wang A; Pyagay PE; Kanwar YS; Chen S
J Am Soc Nephrol; 2006 Nov; 17(11):3093-104. PubMed ID: 16988063
[TBL] [Abstract][Full Text] [Related]
22. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.
Jia ZH; Liu ZH; Zheng JM; Zeng CH; Li LS
Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):571-6. PubMed ID: 17943690
[TBL] [Abstract][Full Text] [Related]
23. Deletion of pro-angiogenic factor vasohibin-2 ameliorates glomerular alterations in a mouse diabetic nephropathy model.
Masuda K; Tanabe K; Ujike H; Hinamoto N; Miyake H; Tanimura S; Sugiyama H; Sato Y; Maeshima Y; Wada J
PLoS One; 2018; 13(4):e0195779. PubMed ID: 29641565
[TBL] [Abstract][Full Text] [Related]
24. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation.
Usui HK; Shikata K; Sasaki M; Okada S; Matsuda M; Shikata Y; Ogawa D; Kido Y; Nagase R; Yozai K; Ohga S; Tone A; Wada J; Takeya M; Horiuchi S; Kodama T; Makino H
Diabetes; 2007 Feb; 56(2):363-72. PubMed ID: 17259380
[TBL] [Abstract][Full Text] [Related]
25. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria.
Wang A; Ziyadeh FN; Lee EY; Pyagay PE; Sung SH; Sheardown SA; Laping NJ; Chen S
Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1657-65. PubMed ID: 17804483
[TBL] [Abstract][Full Text] [Related]
26. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
[TBL] [Abstract][Full Text] [Related]
27. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice.
Dai C; Yang J; Bastacky S; Xia J; Li Y; Liu Y
J Am Soc Nephrol; 2004 Oct; 15(10):2637-47. PubMed ID: 15466268
[TBL] [Abstract][Full Text] [Related]
28. Proteomics analysis reveals diabetic kidney as a ketogenic organ in type 2 diabetes.
Zhang D; Yang H; Kong X; Wang K; Mao X; Yan X; Wang Y; Liu S; Zhang X; Li J; Chen L; Wu J; Wei M; Yang J; Guan Y
Am J Physiol Endocrinol Metab; 2011 Feb; 300(2):E287-95. PubMed ID: 20959534
[TBL] [Abstract][Full Text] [Related]
29. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy.
Han SY; Jee YH; Han KH; Kang YS; Kim HK; Han JY; Kim YS; Cha DR
Nephrol Dial Transplant; 2006 Sep; 21(9):2406-16. PubMed ID: 16728425
[TBL] [Abstract][Full Text] [Related]
30. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy.
Yamamoto Y; Maeshima Y; Kitayama H; Kitamura S; Takazawa Y; Sugiyama H; Yamasaki Y; Makino H
Diabetes; 2004 Jul; 53(7):1831-40. PubMed ID: 15220208
[TBL] [Abstract][Full Text] [Related]
31. Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes.
Seo JY; Park J; Yu MR; Kim YS; Ha H; Lee HB
Am J Nephrol; 2009; 30(6):481-90. PubMed ID: 19786738
[TBL] [Abstract][Full Text] [Related]
32. [Effect of bone morphogenic protein 7 on nephrin expression and distribution in diabetic rat kidneys].
Xiao HQ; Shi W; Zhang Y; Liang YZ
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Apr; 29(4):671-5. PubMed ID: 19403392
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
Noh H; Oh EY; Seo JY; Yu MR; Kim YO; Ha H; Lee HB
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F729-39. PubMed ID: 19553350
[TBL] [Abstract][Full Text] [Related]
34. Purple corn anthocyanins inhibit diabetes-associated glomerular monocyte activation and macrophage infiltration.
Kang MK; Li J; Kim JL; Gong JH; Kwak SN; Park JH; Lee JY; Lim SS; Kang YH
Am J Physiol Renal Physiol; 2012 Oct; 303(7):F1060-9. PubMed ID: 22791342
[TBL] [Abstract][Full Text] [Related]
35. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy.
Sanchez-Niño MD; Bozic M; Córdoba-Lanús E; Valcheva P; Gracia O; Ibarz M; Fernandez E; Navarro-Gonzalez JF; Ortiz A; Valdivielso JM
Am J Physiol Renal Physiol; 2012 Mar; 302(6):F647-57. PubMed ID: 22169009
[TBL] [Abstract][Full Text] [Related]
36. ONO-1301, a sustained-release prostacyclin analog, ameliorates the renal alterations in a mouse type 2 diabetes model possibly through its protective effects on mesangial cells.
Watatani H; Yamasaki H; Maeshima Y; Nasu T; Hinamoto N; Ujike H; Sugiyama H; Sakai Y; Tanabe K; Makino H
Acta Med Okayama; 2015; 69(1):1-15. PubMed ID: 25703166
[TBL] [Abstract][Full Text] [Related]
37. Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db/db mice.
Sumi A; Yamanaka-Hanada N; Bai F; Makino T; Mizukami H; Ono T
Biol Pharm Bull; 2011; 34(6):824-30. PubMed ID: 21628879
[TBL] [Abstract][Full Text] [Related]
38. Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats.
Cha JJ; Kang YS; Hyun YY; Han SY; Jee YH; Han KH; Han JY; Cha DR
Life Sci; 2013 Jun; 92(23):1118-24. PubMed ID: 23643633
[TBL] [Abstract][Full Text] [Related]
39. Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db/db mouse.
Loeffler I; Rüster C; Franke S; Liebisch M; Wolf G
Am J Physiol Renal Physiol; 2013 Sep; 305(6):F911-8. PubMed ID: 23825071
[TBL] [Abstract][Full Text] [Related]
40. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
